Galapagos is progressing one of the largest pipelines in biotech, with a broad range of disease areas being explored in Phase 2 and Phase 3 with filgotinib, Phase 3 with '1690 and Phase 2 with '1205 in IPF, multiple Phase 1 and Phase 2 studies with other clinical programs, and >20 discovery programs.